Sanner Karin, Conner Peter, Bergfeldt Kjell, Dickman Paul, Sundfeldt Karin, Bergh Torbjörn, Hagenfeldt Kerstin, Janson Per Olof, Nilsson Staffan, Persson Ingemar
Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden.
Fertil Steril. 2009 Apr;91(4):1152-8. doi: 10.1016/j.fertnstert.2008.01.073. Epub 2008 Apr 18.
To study the association between hormonal infertility treatment and ovarian neoplasia.
Historical cohort study.
Three university hospitals in Sweden.
PATIENT(S): A total of 2,768 women assessed and treated for infertility and infertility-associated disorders between 1961 and 1975.
INTERVENTION(S): Exposed women received clomiphene citrate and/or gonadotropins.
MAIN OUTCOME MEASURE(S): Incidence of ovarian neoplasia.
RESULT(S): No overall excess risk of invasive ovarian cancer emerged compared with the general population. In women with gonadotropin treatment for non-ovulatory disorders, the risk was elevated (standardized incidence ratio [SIR] = 5.89; 95% confidence interval [CI] 1.91-13.75); four of the five cases reported hCG treatment only, rendering the biological plausibility uncertain. Multivariate analysis within the cohort indicated that treatment with gonadotropins only was associated with an increased risk of invasive cancer (relative risk = 5.28; 95% CI 1.70-16.47). For borderline tumors, a more than threefold overall increase of tumors (SIR = 3.61; 95% CI 1.45-7.44) was noted; women exposed to clomiphene because of ovulatory disorders showed the highest risk (SIR = 7.47; 95% CI 1.54-21.83).
CONCLUSION(S): Our findings of increased risk of ovarian cancer after gonadotropins and of borderline tumors after clomiphene treatment need to be interpreted with caution. However, concern is raised, and further research on the long-term safety particularly of modern hormonal infertility treatment in IVF programs is warranted.
研究激素性不孕治疗与卵巢肿瘤之间的关联。
历史性队列研究。
瑞典的三家大学医院。
1961年至1975年间共2768名接受不孕及不孕相关疾病评估和治疗的女性。
暴露组女性接受枸橼酸氯米芬和/或促性腺激素治疗。
卵巢肿瘤的发病率。
与普通人群相比,侵袭性卵巢癌总体无额外风险增加。在因无排卵性疾病接受促性腺激素治疗的女性中,风险升高(标准化发病率比[SIR]=5.89;95%置信区间[CI]1.91 - 13.75);报告的5例病例中有4例仅接受了人绒毛膜促性腺激素治疗,这使得生物学合理性存疑。队列内多因素分析表明,仅接受促性腺激素治疗与侵袭性癌症风险增加相关(相对风险=5.28;95%CI 1.70 - 16.47)。对于交界性肿瘤,肿瘤总体增加了三倍多(SIR = 3.61;95%CI 1.45 - 7.44);因排卵障碍接受氯米芬治疗的女性风险最高(SIR = 7.47;95%CI 1.54 - 21.83)。
我们关于促性腺激素治疗后卵巢癌风险增加以及氯米芬治疗后交界性肿瘤风险增加的发现需要谨慎解读。然而,这引发了关注,有必要对特别是体外受精项目中现代激素性不孕治疗的长期安全性进行进一步研究。